The FDA has approved another abuse-deterrent, extended release opioid analgesic, Hysingla ER. The medication is designed to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment, and for which alternative treatment options are inadequate. It is not approved for as-needed pain relief and usually not for patients who are opioid non-tolerant. Hysingla ER has properties that are expected to reduce, but not totally prevent, abuse of the drug when chewed and then taken orally, or crushed and snorted or injected. The tablet is difficult to crush, break or dissolve. It also forms a viscous hydrogel (thick gel) and cannot be easily prepared for injection. As a single-entity opioid, Hysingla ER does not carry the serious liver toxicity risks associated with hydrocodone combination products containing acetaminophen.
Read the full release from the FDA here.